Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin and Empagliflozin in Insulin-Resistant Patients With Heart Failure With Reduced Ejection Fraction
2017-004149-26Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in heart failure with reduced ejection fraction (HFrEF), heart failure with mid-range ejection fraction (HFmrEF) and insulin resistance (IR) comparing Metformin, Empagliflozin and Placebo (3 arms). Started Mar 2018; status: completed.
02
Drugs
metforminempagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)heart failure with mid-range ejection fraction (HFmrEF)insulin resistance (IR)
Beyond the preview
Go deeper on 2017-004149-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004149-26.